Navigation Links
RQx Pharmaceuticals and Genentech Enter Drug Discovery Collaboration to Develop Novel Drug Compounds
Date:2/12/2013

LA JOLLA, Calif., Feb. 12, 2013 /PRNewswire/ -- RQx Pharmaceuticals, Inc. today announced that it has entered into a drug discovery collaboration with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for the discovery and development of novel drug compounds for an undisclosed target. Under the terms of the agreement, RQx will receive an up-front payment and is eligible to receive research and development milestone payments totaling $111 million.  In addition, RQx is eligible to receive royalties on sales of products resulting from the collaboration.

"We have made tremendous progress at RQx since the company's founding two years ago, and we are pleased to be moving forward in partnership with Genentech to bring new drugs to market," said Court Turner, CEO of RQx and venture partner at Avalon Ventures.

RQx Pharmaceuticals was founded by Avalon Ventures in 2010 with Floyd Romesberg , Ph.D., a professor at The Scripps Research Institute (La Jolla, CA) and two former graduate students of the Romesberg Lab.  Avalon Ventures formed the company, then seeded and led the Company's Series A financing, which also included an investment from Correlation Ventures. 

"We see a unique opportunity to apply Genentech's expertise in drug discovery and development with the innovation and focus of RQx, to develop a new class of novel drug compounds," said James Sabry , senior vice president of partnering at Genentech.

About RxQ Pharmaceuticals, Inc.

RQx Pharmaceuticals is a biopharmaceutical company developing broad-spectrum small molecule antibiotics to combat serious life threatening infections, including those caused by multi drug-resistant Gram-negative bacteria. To address the growing threat of MDR bacteria, RQx is developing novel, first-in-class antibiotics that evade the current abundance of
'/>"/>

SOURCE RQx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results
2. Jazz Pharmaceuticals To Report 2012 Fourth Quarter And Full Year Financial Results On February 26, 2013
3. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
4. Perrigo Company Acquires U.K.-based Rosemont Pharmaceuticals Ltd. For Approximately £180 Million Or $283 Million
5. Inovio Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
7. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
8. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
9. Shares of Oramed Pharmaceuticals Are Approved for Listing on the Nasdaq Capital Market
10. Avanir Pharmaceuticals Announces Positive Interim Data From Pharmacokinetic Study With Next Generation Compound AVP-786
11. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... and RALEIGH, N.C. , ... Communications, LLC (CTMC), and Integrated Clinical Trial Services, ... and retention for clinical trials announce that they ... Trial Marketing Services (i-CTMS). i-CTMS will provide a ... to pharmaceutical, biotechnology and medical device companies. ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ... "Electrocardiogram (ECG) Devices - Global Trends, Estimates and ... http://photos.prnewswire.com/prnh/20130307/600769 Global Electrocardiogram ... by 2016. The North America ... share while Europe claims approximately ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  Immune Pharmaceuticals ... today that its Board of Directors has elected Mr. Daniel ... who continues as Chief Executive Officer of Immune. Mr. ... since 2013. Immune,s new Chairman, Mr. Daniel ... of shareholders and to continue to support the strategic vision ...
Breaking Medicine Technology:Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4
... 2011 Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ ) ... live webcast on Tuesday, May 3, 2011 at 4:30 p.m. ... will provide a business and financial update and review first ... press release may be accessed from the Investors section of ...
... April 21, 2011 Onyx Pharmaceuticals, Inc. (Nasdaq: ... and teleconference with management to discuss first quarter 2011 financial ... Wednesday, May 4, 2011, at 8:00 a.m. Eastern Time (5:00 ... for the first quarter ended March 31, 2011 will be ...
Cached Medicine Technology:Onyx Pharmaceuticals Announces First Quarter 2011 Financial Results Teleconference and Webcast 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... member can be stressful and can pose health threats to ... Development and Family Studies, Penn State, received a $3 million ... effects of caregiving on familial caregivers. He will look at ... adult day care impacts the stress levels of all individuals ...
... halo surrounding highly-publicized marketing campaigns regarding sweetener reformulations is ... Starbucks and other brands that they will remove high ... into question in news articles by several experts and ... companies, marketing efforts and put forth scientifically substantiated facts ...
... June 30 MicroMass Communications, Inc., a leader in ... appointed veteran business executive and marketing strategist Richard Patterson ... He will spearhead the agency,s oncology business, reporting to ... , , Patterson brings almost three decades ...
... June 30 Delaware,s Partnership to Fight Chronic Disease (PFCD), ... a major part of comprehensive health reform, hosted a breakfast ... for chronic disease management and care. , ... every year and 75 percent - or $1.7 trillion - ...
... NDA - AllerNaze(TM) , , BSE: 500257 NSE: ... , MUMBAI, India, June 30 Pharmaceutical Major, Lupin Ltd. ... steroid (INS) product, AllerNaze(TM) (triamcinolone acetonide, USP) Nasal Spray, 50mcg ... will be the first market in which Lupin will launch ...
... women who feel sensitive to rejection based on their physical ... surgery than those who are less sensitive to appearance-based rejection. ... comments about their physical appearance. The ... Body Image , was conducted by Lora E. Park, ...
Cached Medicine News:Health News:Caregivers may benefit from adult day care 2Health News:Recent News Reports of Sweetener Reformulations Raise Questions About Motivations 2Health News:Recent News Reports of Sweetener Reformulations Raise Questions About Motivations 3Health News:MicroMass Hires Veteran Relationship Marketing Strategist Richard Patterson As VP, Group Account Director 2Health News:MicroMass Hires Veteran Relationship Marketing Strategist Richard Patterson As VP, Group Account Director 3Health News:Delaware's Partnership to Fight Chronic Disease Breakfast Highlights Promising Practices in Managing Chronic Disease Provides Solutions for Reduced Spending and Improved Patient Health 2Health News:Lupin Expands Branded Play 2Health News:Lupin Expands Branded Play 3Health News:Cosmetic surgery appeals to men, women with appearance-based rejection sensitivity 2
Lyphochek Whole Blood Metals Control contains the major heavy metals of toxicological and environmental importance for whole blood analysis....
Lyphochek Whole Blood Control is a unique product designed to monitor immunosuppressants, red cell folate and lead in whole blood assays. This control has three critical levels for each analyte and i...
qUAntify Plus Control is a combination urine dipstick and microscopic control. The control is available in either 12 mL centrifuge tubes or 120 mL flip-top squeeze bottles....
Lyphochek Maternal Serum Control is a trilevel product with analytes at clinically significant levels to monitor maternal serum analysis....
Medicine Products: